Low-Dose Mycophenolate Mofetil for Treatment of Neuromyelitis Optica Spectrum Disorders: A Prospective Multicenter Study in South China.

摘要: Objective: To evaluate the efficacy and safety of low-dose mycophenolate mofetil (MMF, 1,000 mg/day) treatment neuromyelitis optica spectrum disorders (NMOSDs). Methods: This study was a multicenter, open, prospective, follow-up clinical trial. The data include retrospective from pretreatment phase prospective post-treatment phase. From September 2014 to February 2017, NMOSD patients seropositive for aquaporin 4-IgG (AQP4-IgG) were treated with MMF. Results: Ninety MMF median duration 18 months (range 6–40 months). annual recurrence rate (ARR) decreased 1.02 before 0 (P < 0.0001) after treatment, Expanded Disability Status Scale (EDSS) score 4 3 0.0001). EDSS significantly lower = 0.038) first 90 days treatment. serum AQP4-IgG titer in 50 cases (63%). Simple McGill pain (SF-MPQ) reduced 65 (88%) myelitis 17 0–35) 11 0–34) Hauser walking index (Hauser Walk Rating Scale) 2 1–9) 1 0–7) Adverse events documented 43% patients, eight discontinued due intolerable adverse events. Fourteen (16%) total our last various reasons switched azathioprine or rituximab. Conclusion: Low-dose relapse disability South China. However, some still suffered at this dosage. Clinical Trial Registration: www.ClinicalTrials.gov, identifier : {"type":"clinical-trial","attrs":{"text":"NCT02809079","term_id":"NCT02809079"}}NCT02809079.